[{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Clinton Health Access Initiative","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Dolutegravir Sodium","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viatris \/ Clinton Health Access Initiative","highestDevelopmentStatusID":"15","companyTruncated":"Viatris \/ Clinton Health Access Initiative"},{"orgOrder":0,"company":"Viatris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Abacavir","moa":"||HIV integrase strand transfer","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viatris \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Viatris \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"AIDS Healthcare Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"ViiV Healthcare \/ AIDS Healthcare Foundation","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ AIDS Healthcare Foundation"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Abacavir","moa":"||HIV integrase strand transfer","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Abacavir","moa":"||HIV integrase strand transfer","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viatris \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Viatris \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Abacavir","moa":"||HIV integrase strand transfer","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Abacavir","moa":"||HIV integrase strand transfer","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ViiV Healthcare \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Pfizer Inc"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Abacavir","moa":"||HIV integrase strand transfer","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Fundaci\u00f3n Hu\u00e9sped","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ViiV Healthcare \/ Fundaci\u00f3n Hu\u00e9sped","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Fundaci\u00f3n Hu\u00e9sped"},{"orgOrder":0,"company":"ACTG","sponsor":"ViiV Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ACTG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ACTG \/ ViiV Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"ACTG \/ ViiV Healthcare"}]
Find Clinical Drug Pipeline Developments & Deals for Dolutegravir
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
Synergice, a Strides Pharma initiative, is a new gen B2B platform for diverse portofolio needs.
